Shares of Nuvalent (NUVL) surged 39.28% to $123.25 in early trading Tuesday after GSK plc (GSK) announced a definitive agreement to acquire the oncology-focused biotech for $124 per share in cash, a total enterprise value of approximately $10.6 billion. The stock now trades just $0.75 below the offer price, reflecting a narrow 0.6% spread that signals the market expects the deal to close with limited friction.
The transaction transforms Nuvalent from a high-risk biotech bet into a classic merger-arbitrage play. Investors are now closely monitoring the tender offer timetable, antitrust clearance under the Hart-Scott-Rodino Act, and upcoming FDA decision dates for two late-stage lung-cancer therapies. GSK plans to launch a tender offer for all outstanding Class A and Class B shares within 10 business days, a structure designed to expedite the takeover by paying shareholders directly in cash.
The $124 offer represents a 40% premium over Nuvalent's closing price before the announcement and a 26% premium over its 30-day volume-weighted average price (VWAP). To secure the deal, GSK already has commitments from Deerfield Management-linked entities and certain Nuvalent directors and officers to tender approximately 28% of the outstanding Class A shares. The Nuvalent board has unanimously recommended that shareholders accept the offer.
The transaction is subject to a majority of Class A shares being tendered and U.S. antitrust review, but there is no financing condition. A breakup fee of $350.475 million is in place if Nuvalent accepts a superior proposal or changes its recommendation. While a higher bid could theoretically emerge, the deal terms make a GSK acquisition the most likely outcome.
GSK is gaining more than a single drug. The acquisition brings zidesamtinib and neladalkib, both late-stage kinase inhibitors targeting specific genetic forms of non-small cell lung cancer (NSCLC), the most common form of lung cancer. Each drug holds FDA Breakthrough Therapy and Orphan Drug designations. The FDA action date for zidesamtinib is September 18, 2026, and for neladalkib, November 27, 2026. GSK also acquires NVL-330, an early-stage HER2 inhibitor for HER2-altered NSCLC, along with Nuvalent's preclinical pipeline.
GSK CEO Luke Miels stated that the deal provides "immediate new sales growth opportunities" and creates a platform in lung cancer for Ris-Rez, the company's B7-H3 antibody-drug conjugate currently in Phase 3. GSK expects the acquisition to contribute to revenue from 2027 and to boost core operating profit and core EPS in 2027 and 2029 after synergies are realized. However, if the deal closes in the third quarter of 2026, GSK anticipates low single-digit percentage dilution to core EPS in 2026, 2027, and 2028.
Analysts have recalibrated their views. TD Cowen downgraded Nuvalent to Hold with a $124 price target, while Guggenheim lowered its rating to Neutral and cut its target from $151 to $124. The stock is now being treated as a takeout candidate rather than a standalone biotech, with the cash bid capping upside.
Even if the Nuvalent deal closes, GSK will face stiff competition in the ALK-positive lung cancer market from established drugs such as Pfizer's Lorbrena and Roche's Alecensa. These competitive dynamics will have a greater impact on GSK's long-term returns than on Nuvalent's near-term trading. Investors are also watching how the FDA handles labeling, safety warnings, and launch plans for the acquired assets.
Risks remain. The deal requires sufficient shareholder tenders, antitrust clearance, and no legal or regulatory obstacles. Nuvalent's filings caution that FDA approval may not occur on schedule or at all, and early trial data may not predict final results. If the deal collapses, the stock would likely trade down to a level reflecting its drug risk rather than the cash offer.
The next key milestones include GSK's Schedule TO and Nuvalent's Schedule 14D-9 statement, which will detail the tender offer mechanics. After that, attention shifts to the FDA: zidesamtinib on September 18 and neladalkib on November 27. These two catalysts, despite neither drug having U.S. approval yet, drove GSK to commit $10.6 billion upfront.
